Clinical trial ACTRN12618001868279
Status: Recruiting (according to the registry)Phase 2Latest change: Source: ANZCTR (Australia, New Zealand) (via WHO ICTRP)
What's on this page?
This record’s status may be out of date
The trial was registered in November 16, 2018 and still shows as "recruiting" in the registry. Status information in other countries’ registries is often not updated; the trial may have ended or stopped. For current information, check the record itself.
Information in the record
Original title: Clinical study Of caNNabidiol in children and adolesCenTs with Fragile X Open-Label Extension (CONNECT-FX OLE)
- Record number
- ACTRN12618001868279
- Registry
- ANZCTR (Australia, New Zealand) (via WHO ICTRP)
- Status
- Recruiting (according to the registry)
- Type and phase
- Clinical trial, phase 2
- Participants
- Target: 300
- Condition (as registered)
- Fragile X Syndrome, Human Genetics and Inherited Disorders - Other human genetics and inherited disorders, Neurological - Other neurological disorders
- Countries
- Australia, New Zealand, United States
- Topic in the guide
- Outside the topics in the guide
Timeline
According to the ANZCTR (Australia, New Zealand) (via WHO ICTRP) record. Future dates are the investigator’s estimates and may change.
- Registration: November 16, 2018
History
We check the record once a month via WHO ICTRP; here are the changes we have seen since we started tracking it, newest first.
- : Added to tracking. Status: Recruiting.
Results
No results have been published yet. When they are, they will appear here. A trial being under way does not mean CBD works for this condition; only the results can show that.
All ongoing trials · Thinking of taking part? Which specialist to see